Universitätsklinikum Frankfurt, Department of Internal Medicine II
Welcome,         Profile    Billing    Logout  
 4 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stephan, Christoph
EAGLE-1, NCT04010539 / 2018-001780-23: A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

Completed
3
628
Europe, US, RoW
Gepotidacin, Ceftriaxone, Azithromycin
GlaxoSmithKline, BARDA
Gonorrhea
10/23
10/23
NCT03696160 / 2018-003481-13: The Late Presenter Treatment Optimisation Study

Completed
3
447
Europe
Biktarvy, Symtuza
NEAT ID Foundation, Gilead Sciences, Janssen Pharmaceuticals
HIV/AIDS
06/24
06/24
VOGUE, NCT05979311: A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

Recruiting
3
412
Europe, Japan, RoW
Dolutegravir, Lamivudine, Bictegravir, Emtricitabine, Tenofovir alafenamide
ViiV Healthcare
HIV, HIV Infections
11/25
10/26
NCT01056185: Respiratory Virus Hospitalization Study (FLU 003 Plus)

Completed
N/A
1000
Europe, US, RoW
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Clinical & Translational Science Institute, University of Minnesota
Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
08/24
08/24
NCT04090151: The RESPOND Outcomes Study

Recruiting
N/A
37853
Europe, RoW
Rigshospitalet, Denmark, Gilead Sciences, ViiV Healthcare
HIV
12/25
12/25
MISTRAL, NCT05421286: The Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events

Active, not recruiting
N/A
1000
Europe, RoW
Rigshospitalet, Denmark, IrsiCaixa, Horizon 2020 - European Commission
HIV-1-infection, Inflammation, AIDS
12/25
12/25
Ebeling, Franziska
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24

Download Options